After Nektar stops clinical trials for key cancer drug its shares decline
Nektar Therapeutics recently decided to stop all trials involving its key cancer drug due its failure in multiple studies. However, this announcement dragged the drug developer’s shares down by 23 per cent in after-market trading. The trials that the durg maker stopped included those involving a combination of bempegaldesleukin with Bristol Myers Squibb Co’s cancer …